Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07215312 | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | PHASE2 | RECRUITING | 100 | — | — | Oct 13, 2025 | Dec 1, 2026 | May 22, 2026 | 26 | United States, Argentina |
| Arm | Type | Description |
|---|---|---|
| LY3938577 | EXPERIMENTAL | Participants will receive LY3938577 subcutaneously (SC) |
| Degludec | ACTIVE_COMPARATOR | Participants will receive degludec SC |
| Name | Type | Description |
|---|---|---|
| LY3938577 | DRUG | Administered SC |
| Degludec | DRUG | Administered SC |
Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)...